Written question asked by Jesse Norman (Conservative) on Wednesday, 24 November 2021, in the House of Commons. It was due for an answer on Thursday, 2 December 2021 (named day). It was answered by Edward Argar (Conservative) on Thursday, 2 December 2021 on behalf of the Department of Health and Social Care.
Odevixibat
- Question
-
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of Odevixibat for treating processive familial intrahepatic cholestasis.
- Answer
-
The Department has made no assessment. The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based recommendations for the National Health Service on whether licenced medicines represent a clinically and cost-effective use of resources.
NICE is currently appraising odevixibat for the treatment of progressive familial intrahepatic cholestasis through its highly specialised technologies programme and expects to publish final guidance in January 2022.
Secondary information
- Type
- Written question
- Reference
- 80971
- Session
- 2021-22
- Subjects
- Odevixibat
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2021-12-02 12:34:38 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2021-22/80971
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2021-22/80971
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2021-22/80971